Clinical trials: sponsored by Alcon Research
Age Related Macular Degeneration
WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.
- Trial name
- NCT00992563
- Testing
- AL-39324 ophthalmic suspension, Ranibizumab 10 mg/mL
- Volunteers
- 35 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation
The purpose of this study is to assess the safety and efficacy of AL-38583 in the treatment of the signs of inflammation associated with allergic conjunctivitis.
- Trial name
- NCT01001091
- Testing
- AL-38583 ophthalmic solution, AL-38583 ophthalmic solution vehicle, Dexamethasone ophthalmic suspension, 0.1%
- Volunteers
- 312 people
- Sponsor
- Alcon Research
Dry Eye
A Study of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) Versus Vehicle in Dry Eye Patients
The purpose of this study is to demonstrate efficacy of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) ophthalmic gel compared to Vehicle for the treatment of dry eye.
- Trial name
- NCT00840268
- Testing
- Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel, Hydroxypropyl Guar Galactomannan Vehicle
- Volunteers
- 427 people
- Sponsor
- Alcon Research
Exudative Age-Related Macular Degeneration
ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
The purpose of this study was to assess the safety, tolerability, and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared with LUCENTIS® in patients with exudative…
- Trial name
- NCT01304693
- Testing
- ESBA1008 solution, Ranibizumab 0.5 mg
- Volunteers
- 376 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of Travoprost/Timolol BAC-free
The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00760539
- Testing
- Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, Travoprost 0.004%/Timolol 0.5% ophthalmic solution
- Where
- Japan
- Volunteers
- 87 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00672997
- Testing
- Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, Travoprost 0.004%/Timolol 0.5% ophthalmic solution
- Volunteers
- 301 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of AL-39256 in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00761709
- Testing
- AL-39256 Ophthalmic Suspension, 1%, Latanoprost Ophthalmic Solution, 0.005%, Vehicle
- Volunteers
- 104 people
- Sponsor
- Alcon Research
Dry Eye
A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye
The purpose of this study is to determine whether AL-38583 ophthalmic solution is effective for treatment of signs and symptoms of dry eye.
- Trial name
- NCT00893139
- Testing
- AL-38583 ophthalmic solution 0.05%, AL-38583 ophthalmic solution 0.10%, AL-38583 vehicle
- Volunteers
- 765 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health
The purpose of this study is to understand differences in visual function-related patient-reported outcomes between a non-BAK medication (Travoprost APS) and a BAK-preserved medication (XALATAN®) in patients with open-angle…
- Trial name
- NCT00892762
- Testing
- Travoprost APS 40 micrograms/ml eye drop solution, Latanoprost 50 micrograms/ml eye drop solution
- Volunteers
- 434 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Patient Preference Study
In this randomized crossover study, patients will receive a single drop of two test articles and assess comfort.
- Trial name
- NCT00576342
- Testing
- AL-3862+timolol ophthalmic suspension, Dorzolamide+timolol ophthalmic solution
- Volunteers
- 129 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open-angle Glaucoma
Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00670033
- Testing
- Travoprost ophthalmic solution (new formulation), Travoprost ophthalmic solution, 0.004%, Vehicle
- Volunteers
- 158 people
- Sponsor
- Alcon Research
Acute Otitis Externa
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
The purpose of this study was to demonstrate the superiority of AL-60371, 0.3% Otic Suspension relative to AL-60371 Vehicle based on clinical cures at test-of-cure (TOC) for the treatment of acute otitis externa (AOE).
- Trial name
- NCT01535599
- Testing
- AL-60371, 0.3% Otic Suspension, AL-60371 Vehicle
- Volunteers
- 768 people
- Sponsor
- Alcon Research
Geographic Atrophy, Age-Related Macular Degeneration
Geographic Atrophy Treatment Evaluation
The purpose of this study was to evaluate the safety and efficacy of AL-8309B Ophthalmic Solution versus Vehicle administered as a topical ocular drop for the treatment for geographic atrophy (GA) secondary to age-related macular…
- Trial name
- GATE (NCT00890097)
- Testing
- AL-8309B Ophthalmic Solution, AL-8309B Vehicle
- Volunteers
- 772 people
- Sponsor
- Alcon Research
Macular Degeneration
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related…
- Trial name
- NCT00041483
- Testing
- Anecortave Acetate 15 mg sterile suspension, Photodynamic Therapy (PDT)
- Where
- United States
- Volunteers
- 530 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior brimonidine 0.2%/timolol 0.5% fixed combination (COMBIGAN®) therapy in patients with open-angle glaucoma or ocular…
- Conditions
- Glaucoma, Ocular Hypertension, Open-angle Glaucoma
- Trial name
- NCT01415401
- Testing
- Brinzolamide 1% / timolol 0.5% maleate fixed combination
- Volunteers
- 57 people
- Sponsor
- Alcon Research
Myopia, Hyperopia
Subjective Comparison of Pre-Lens Tear Film Stability With Daily Disposable Contact Lenses
The purpose of this study was to compare three CE-marked daily disposable contact lenses for tear film stability as measured by pre-lens non-invasive keratograph break up time (PL NIK-BUT).
- Conditions
- Myopia, Hyperopia, Refractive Error
- Trial name
- NCT01839318
- Testing
- Nelfilcon A contact lenses, Omafilcon A contact lenses, Etafilcon A contact lenses
- Volunteers
- 30 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
Efficacy of Changing to TRAVATAN® From Prior Therapy
The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® solution without BAK (benzalkonium chloride) after changing from prior latanoprost 0.005% ophthalmic solution monotherapy in subjects with…
- Trial name
- NCT01510145
- Testing
- Travoprost 0.004% BAK-free
- Volunteers
- 191 people
- Sponsor
- Alcon Research
Myopia, Ametropia
Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens
The purpose of this study was to demonstrate substantial equivalence of the new DAILIES® AquaComfort Plus® Multifocal (DACP MF) contact lens to the commercially available Focus® DAILIES® Progressives (FDP) contact lens.
- Conditions
- Myopia, Ametropia, Presbyopia, Refractive Error
- Trial name
- NCT01797783
- Testing
- Nelfilcon A multifocal contact lens with comfort additive, Nelfilcon A multifocal contact lens
- Volunteers
- 83 people
- Sponsor
- Alcon Research
Adenoviral Conjunctivitis
An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis
The purpose of this study is to evaluate the safety and efficacy of AL-46383A Ophthalmic Solution for the treatment of adenoviral conjunctivitis.
- Trial name
- NCT00901693
- Testing
- AL-46383A Ophthalmic Solution, AL-46383A Ophthalmic Solution Vehicle
- Volunteers
- 452 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research